Investegate |Lloyds Banking Group Announcements | Lloyds Banking Group: Director/PDMR Shareholding investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
(0)
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) AvantGen, a San Diego-based biotech, is a leader in the use of yeast display technology for human and rabbit monoclonal antibody discovery and optimization. AvantGen has received an award from the NIH s RADx Next program to expedite the commercialization of its high affinity rabbit monoclonal antibodies against the nucleocapsid (N) protein of SARS-CoV-2. A pair of the antibody clones has been evaluated extensively in a rapid lateral flow assay (LFA) format for the detection of SARS-CoV-2 N protein. The results demonstrated the test is highly sensitive and superior to many current marketed antigen tests.
Article content
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) AvantGen, a San Diego-based biotech, is a leader in the use of yeast display technology for human and rabbit monoclonal antibody discovery and optimization. AvantGen has received an award from the NIH’s RADx Next program to expedite the commercialization of its high affinity rabbit monoclonal antibodies against the nucleocapsid (N) protein of SARS-CoV-2. A pair of the antibody clones has been evaluated extensively in a rapid lateral flow assay (LFA) format for the detection of SARS-CoV-2 N protein. The results demonstrated the test is highly sensitive and superior to many current marketed antigen tests.
25 may 2021
AvantGen receives an award from the NIH/RADx to commercialize its anti-SARS-CoV-2 nucleocapsid antibodies for ultra-high sensitivity lateral flow assay development
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) AvantGen, a San Diego-based biotech, is a leader in the use of yeast display technology for human and rabbit monoclonal antibody discovery and optimization. AvantGen has received an award from the NIH’s RADx Next program to expedite the commercialization of its high affinity rabbit monoclonal antibodies against the nucleocapsid (N) protein of SARS-CoV-2. A pair of the antibody clones has been evaluated extensively in a rapid lateral flow assay (LFA) format for the detection of SARS-CoV-2 N protein. The results demonstrated the test is highly sensitive and superior to many current marketed antigen tests.